Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS. However, tocilizumab and siltuximab are expensive and some patients fail to respond to anti-IL-6 therapy, which urges the need for new drugs. In clinical practice, we found some patients with multiple myeloma developed markedly increased levels of tumor necrosis factor (TNF)-alpha during the CRS period after anti-BCMA CAR T cell infusion. Here we present the successful use of TNF-alpha inhibitor (etanercept) to cure CRS in three patients. The introduction of etanercept did not alter patients' response to CAR T cell therapy and no adverse event was observed directly related to the administration of etanercept. Furthermore, in vitro experiments confirmed that etanercept did not affect the proliferation and effector function of CAR T cells. Our results indicate that etanercept could be considered as a treatment option for CRS in patients with significantly elevated TNF-alpha levels.

Automated summary

Etanercept could be considered as a treatment option for CRS in patients with significantly elevated TNF-alpha levels, as shown in successful treatment of three multiple myeloma patients, without affecting CAR T cell efficacy and causing any observed adverse events.